# Study of IBI363 in Patients with Advanced First-line Gastric Cancer

> **NCT06610799** · PHASE1 · RECRUITING · sponsor: **Xiangdong Cheng** · enrollment: 40 (estimated)

## Conditions studied

- IBI363 + Chemotherapy

## Interventions

- **DRUG:** IBI363

## Key facts

- **NCT ID:** NCT06610799
- **Lead sponsor:** Xiangdong Cheng
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06610799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06610799, "Study of IBI363 in Patients with Advanced First-line Gastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06610799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*